Терапия ингибиторами PCSK9 (алирокумаб) пациентов с ишемическим инсультом в Республике Коми

G. M.  Ponomareva; M. S.  Cherepianskii; V. V.  Dudayte; R. M.  Abackarov

doi:10.34687/2219-8202.JAD.2024.01.0002

Authors

G. M. Ponomareva Pitirim Sorokin State University, Syktyvkar
M. S. Cherepianskii Komi Republican Clinical Hospital, Syktyvkar
V. V. Dudayte Komi Republican Clinical Hospital, Syktyvkar
R. M. Abackarov Komi Republican Clinical Hospital, Syktyvkar

DOI:

https://doi.org/10.34687/2219-8202.JAD.2024.01.0002

Keywords:

carotid atherosclerosis, fatty acids, fatty acid balance

Abstract

Background. Hyperlipidemia is the main risk factor for diseases caused by atherosclerosis, including ischemic stroke.
Objective. Improving the care of patients with stroke, dyslipidemia in the Komi Republic based on the study of the effect of PCSK9 inhibitor (alirocumab) on total cholesterol and low-density lipoproteid
cholesterol in patients with ischemic stroke on the basis of the neurological department
for the treatment of patients with acute cerebral circulatory disorders (regional vascular center) of the Komi Republic. Assessment of neurological, mental status, mobility index in patients with ischemic stroke at the time of admission and discharge from the hospital.
Materials and methods: the use of the drug alirocumab (praluent) 150 mg in the regional vascular center of the Komi Republic (Syktyvkar) in May-November 2021 in nineteen patients with a verified diagnosis of ischemic stroke. The levels of total cholesterol and low-density lipoproteid
cholesterol were evaluated, the NIHSS scales, the Rivermead mobility index, the Rankin scale, the Glasgow Coma scale in patients with ischemic stroke were also evaluated.
Results: all patients achieved the target levels of total cholesterol and low-density lipoprotein cholesterol at the time of discharge (p<0,05). The indicators of patients with ischemic stroke on the NIHSS scale, the Rankin scale, the Glasgow Coma Scale improved slightly by discharge, without
significant differences. When assessing the Rivermead mobility index, they significantly improved by discharge (p <0,05).

Downloads

Download data is not yet available.

References

Voznyuk I.A., Shamalov N.A., Ezhov M.V., Tikhomirova O.V., Gurevich V.S., Kucherenko S.S. and others. Optimization of lipid-lowering therapy in patients who have suffered ischemic stroke. Resolution of the Council of Experts. Journal of Neurology and Psychiatry. S.S. Korsakov. 2020; 120(6): 152–161.Russian. (Вознюк И.А., Шамалов Н.А., Ежов М.В., Тихомирова О.В, Гуревич В.С., Кучеренко С.С. и др. Оптимизация гиполипидемической терапии у пациентов, перенесших ишемический инсульт. Резолюция Совета экспертов. Журнал неврологии и психиатрии им. С.С. Корсакова. 2020; 120(6): 152–161). https://doi.org/10.17116/jnevro2020120061152

Ezhov M.V., Sergienko I.V., Aronov D.M., Arabidze G.G., Akhmedzhanov N.M., Bazhan S.S. and others. Diagnosis and correction of lipid metabolism disorders to prevent atherosclerosis. Russian recommendations, VI revision. Atherosclerosis and dyslipidemia. 2017; 3:5-22. Russian. (Ежов М.В., Сергиенко И.В., Аронов Д.М., Арабидзе Г.Г., Ахмеджанов Н.М., Бажан С.С. и др. Диагностика и коррекция нарушений липидного обмена с целью профилактики атеросклероза. Российские рекомендации, VI пересмотр. Атеросклероз и дислипидемии. 2017; 3: 5-22).

Skvortsova V.I., Shetova I.M., Kakorina E.P. Organization of care for patients with stroke in Russia. Results of 10 years of implementation of a set of measures to improve medical care for patients with acute cerebrovascular accidents. Annals of Clinical and Experimental Neurology. 2018; 12(3): 5-12. Russian. (Скворцова В.И., Шетова И.М., Какорина Е.П. Организация помощи пациентам с инсультом в России. Итоги 10 лет реализации комплекса мероприятий по совершенствованию медицинской помощи пациентам с острыми нарушениями мозгового кровообращения. Aнналы клинической и экспериментальной неврологии. 2018; 12(3): 5-12.) DOI: 10.25692/ACEN.2018.3.1

Sergienko I.V., Shestakova M.V., Boytsov S.A., Ametov A.S., Antsiferov M.B., Kukharchuk V.V. et al., Extreme risk category in the system of stratification of cardiovascular complications. Advisory board consensus. Atherosclerosisdislipidemia. 2018; No. 4(33): 8-16. Russian. (Сергиенко И.В., Шестакова М.В., Бойцов С.А., Аметов А.С., Анциферов М.Б., Кухарчук В.В. и др., Экстремальная категория риска в системе стратификации сердечно-сосудистых осложнений. Консенсус консультативного совета. Атеросклероз и дислипидемии. 2018; №4(33): 8-16).

Tsimikas S, Fazio S, Ferdinand KC, Ginsberg HN, Koschinsky ML, Marcovina SM et al. NHLBI working group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis. Journal of the American College of Cardiology. 2018; 71(2):177-192.

Ahmed N, Audebert H, Turc G, Cordonnier C, Christensen H, Sacco S et al. Consensus statements and recommendations from the ESO-Karolinska Stroke Update Conference, Stockholm 11—13 November 2018. European Stroke Journal. 2019;4(4):307-317. https://doi.org/10.1177/2396987319863606

MachF, BaigentC, CatapanoAL, KoskinasKC, CasulaM, BadimonLetal. ESCScientificDocumentGroup. 2019 ESC/EASGuidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). EuropeanHeartJournal. 2020;41(1):111-188. https://doi.org/10.1093/eurheartj/ehz455

Zhao Z, Du S, Shen S, Luo P, Ding S, Wang Get al. Comparative efficacy and safety of lipid-lowering agents in patients with hypercholesterolemia: A frequentist network meta-analysis. Medicine. 2019; 98(6):e14400. https://doi.org/10.1097/MD.0000000000014400

Galstyan G.R., Galyavich A.S., Grineva A.S., Gurevich V.S., Ezhov M.V., Kalashnikov V.Y. Possibilities of lipid-lowering therapy in improving the prognosis in patients with atherosclerotic cardiovascular diseases and diabetes mellitus: the role of PCSK9 inhibitors. Russian Journal of Cardiology. 2018; 23 (12): 103-106. Russian. (Галстян Г.Р., Галявич А.С., Гринева А.С., Гуревич В.С., Ежов М.В., Калашников В.Ю. Возможности липидснижающей терапии в улучшении прогноза у пациентов с атеросклеротическими сердечно-сосудистыми заболеваниями и сахарным диабетом: роль ингибиторов PCSK9. Российский кардиологический журнал. 2018; 23 (12): 103-106). http://dx.doi.org/10.15829/1560-4071-2018-12-103-106

Kukharchuk V.V., Ezhov M.V., Sergienko I.V., Arabidze G.G., BubnovaM. G., Balakhonova T.V. and others. Atherosclerosis and dyslipidemia. Diagnosis and correction of lipid metabolism disorders for the prevention and treatment of atherosclerosis. Russian recommendations, VII revision. Atherosclerosis and dyslipidemia. 2020;1(38):7-42. Russian. (Кухарчук В.В., Ежов М.В., Сергиенко И.В., Арабидзе Г.Г., Бубнова М.Г., Балахонова Т.В. и др. Атеросклероз и дислипидемии. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации,VII пересмотр. 2020;1(38):7-42). DOI: 10.34687/2219-8202.JAD.2020.01.0002

Piradov M.A. STROKE. Step-by-step instruction. 2nd edition, revised and expanded. Ed. M.A. Piradov, M.Yu. Maksimova: GEOTAR-media; 2020. 288s. Russian. (Пирадов М.А. ИНСУЛЬТ. Пошаговая инструкция. 2-е издание, переработанное и дополненное. Под.ред. М.А. Пирадов, М.Ю. Максимова.:ГЭОТАР-медиа; 2020. 288с).

Powers WJ, Rabinstein AA, Ackerson Tet al. 2018 Guidelines for the Early Management of Patients with Acute Ischemic Stroke: a Guideline for Healthcare Professionals from the American Heart Association. American Stroke Association.2018;49(3): 46–110. doi: 10.1161/STR.0000000000000158

Gusev E.I. Neurology. National leadership. Brief edition. Ed. E.I. Guseva, A.N. Konovalova, A.B. Hext. M.: GEOTAR-Media, 2018. - 688 p. Russian. (Гусев Е.И. Неврология. Национальное руководство. Краткое издание. Под ред. Е.И. Гусева, А.Н. Коновалова, А.Б. Геxт. М.: ГЭОТАР-Медиа, 2018.- 688 с).

Nogueira RG, Jadhav AP, Haussen DC, et al. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. N Engl J Med. 2018;378(1):11–21. doi: 10.1056/NEJMoa1706442

Stakhovskaya L.V., Klochikhina O.A., Bogatyreva M.D. and others. Comparison of the incidence of stroke in certain regions of the Russian Federation (according to the territorial population-based stroke registry, 2009-2014). Medical Bulletin of the North Caucasus. 2019; 14 (1): 64-67. Russian. (Стаховская Л. В., Клочихина О.А., Богатырева М.Д. и др. Сравнение заболеваемости инсультом в отдельных регионах Российской Федерации (по данным территориально-популяционного регистра инсульта, 2009-2014 гг.). Медицинский вестник Cеверного Кавказа. 2019; 14 (1): 64-67). DOI: 10.14300/mnnc.2019.14051

Sabatine M. S. et al. Evolocumab and clinical outcomes in patients with cardiovascular disease //New England Journal of Medicine. – 2017. – Т. 376. – №. 18. – С. 1713-1722.

Blazing MA, Giugliano RP, Cannonet Ch P, et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population. Am Heart J. 2014 Aug;168(2):205-12.e1. doi: 10.1016/j.ahj.2014.05.004.

Schwartz G.G., Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome // New England Journal of Medicine. 2018. Т. 379. № 22. С. 2097–2107. doi: 10.1056/NEJMoa1801174

Amarenco P, Bogousslavsky J, Callahan A, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006 Aug 10;355(6):549-59. doi: 10.1056/NEJMoa061894.